Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus

[1] Powers E(2020)Novel therapies are changing treatment paradigms in metastatic prostate cancer J Hematol Oncol 13 144-715

[2] Karachaliou GS(2020)Advanced prostate cancer: treatment advances and future directions Trends Cancer 6 702-501

[3] Kao C(2019)Prostate radiotherapy in India: evolution, practice and challenges in the 21st century Clin Oncol (R Coll Radiol) 31 492-S13

[4] Harrison MR(2017)Navigating the evolving therapeutic landscape in advanced prostate cancer Urol Oncol 35 S1-13263

[5] Hoimes CJ(2020)Metastatic castration-resistant prostate cancer: academic insights and perspectives through bibliometric analysis Medicine 99 e19760-10

[6] George DJ(2020)A clinical evaluation of enzalutamide in metastatic castration-sensitive prostate cancer: guiding principles for treatment selection and perspectives on research Onco Targets Ther 3 13247-1559

[7] Swami U(2020)Sorting through the maze of treatment options for metastatic castration-sensitive prostate cancer Am Soc Clin Oncol Educ Book 40 1-S50

[8] McFarland TR(2021)Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study Lancet Oncol 22 1541-2033

[9] Nussenzveig R(2020)Is there a role for immunotherapy in prostate cancer? Cells 9 2051-E149

[10] Agarwal N(2021)Microbiota and prostate cancer Semin Cancer Biol 61 S43-547

[1] Powers E(2020)Novel therapies are changing treatment paradigms in metastatic prostate cancer J Hematol Oncol 13 144-715

[2] Karachaliou GS(2020)Advanced prostate cancer: treatment advances and future directions Trends Cancer 6 702-501

[3] Kao C(2019)Prostate radiotherapy in India: evolution, practice and challenges in the 21st century Clin Oncol (R Coll Radiol) 31 492-S13

[4] Harrison MR(2017)Navigating the evolving therapeutic landscape in advanced prostate cancer Urol Oncol 35 S1-13263

[5] Hoimes CJ(2020)Metastatic castration-resistant prostate cancer: academic insights and perspectives through bibliometric analysis Medicine 99 e19760-10

[6] George DJ(2020)A clinical evaluation of enzalutamide in metastatic castration-sensitive prostate cancer: guiding principles for treatment selection and perspectives on research Onco Targets Ther 3 13247-1559

[7] Swami U(2020)Sorting through the maze of treatment options for metastatic castration-sensitive prostate cancer Am Soc Clin Oncol Educ Book 40 1-S50

[8] McFarland TR(2021)Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study Lancet Oncol 22 1541-2033

[9] Nussenzveig R(2020)Is there a role for immunotherapy in prostate cancer? Cells 9 2051-E149

[10] Agarwal N(2021)Microbiota and prostate cancer Semin Cancer Biol 61 S43-547